Lurasidone effective in treating schizophrenia, company said
OSAKA, Japan An investigational drug was effective in treating patients with schizophrenia, according to late-stage clinical trial results announced Wednesday.
Dainippon Sumitomo Pharma Co. said participants in a 2,000-patient phase 3 trial receiving daily 40-mg and 120-mg doses of lurasidone experienced greater improvement than those taking placebo.
“We are pleased with the results of this study as these data reinforce our belief that lurasidone will be an important treatment option for patients with schizophrenia,” Dainippon Sumitomo Pharma CEO Masayo Tada said in a statement.
Tada said the company would submit a regulatory approval application to the Food and Drug Administration early next year.
Winn-Dixie reports Q4, fiscal-year results
JACKSONVILLE, Fla. Winn-Dixie closed out the year on a strong note Monday, reporting $7.4 billion in net sales, up 1.2%, for the fiscal year ended June 24, with identical-store sales from continuing operations up 1.2% compared with the prior fiscal year.
During a conference call Tuesday morning, Winn-Dixie chairman, president and CEO Peter Lynch told analysts that the chain’s remodel program, scheduled to be completed across the chain’s entire store base by fiscal year 2013, will be a key driver in the grocer’s success going forward, as will pharmacy.
“Script counts are up,” noted Lynch. “As far as pharmacy plays into our promotional activity, as I have said in the past, pharmacy is a key component to our strategy going forward,” he said. Primarily because pharmacy customers, no matter which channel from which they pick up their prescriptions, are sticky customers. “So we are always trying to make sure that we keep those customers and reach out to them for more business,” Lynch said.
And right now, that means better customer service than the pharmacy down the street. “We’ve done a lot of work in making sure that our pharmacists are really out there taking care of the customer,” he said. “The customer really needs that approach regarding pharmacy and I think we’re doing a much, much better job at it here at Winn-Dixie today.”
Lynch updated analysts around Winn-Dixie’s store remodeling program, which Winn-Dixie is tackling on a market-by-market basis. The grocer’s hometown market of Jacksonville, Fla., home to 51 stores across north Florida and south Georgia, was completed in mid-July. “We are currently on track to remodel half of our stores by the end of fiscal year 2010 and to complete substantially all of our stores by 2013,” Lynch said.
At the end of fiscal 2009, the company had completed 170 store remodels, 73 of which were still within their first year of operation. Of the 73 first-year store remodels, 47 are considered by the company to be offensive remodels. For fiscal 2009, those 47 stores had a 10.3% weighted average sales increase compared to the same period in the prior fiscal year, excluding the grand re-opening phase. The sales increase resulted from increases in transaction count and basket size of 5.6% and 4.5%, respectively.
Diplomat Specialty Pharmacy, CareSource announce partnership to treat CKD
SWARTZ CREEK, Mich. A specialty pharmacy in the Midwest will partner with another company to help treat people with chronic kidney disease.
Diplomat Specialty Pharmacy announced this week that its Diplomat Health Services Division would partner with Ohio-based CareSource in an effort to slow the progression of kidney disease, improve clinical outcomes and reduce costs associated with it.
“Early recognition and intervention are essential to slowing disease progression and improving outcomes,” CareSource chief medical officer Craig Thiele said in a statement. “Collaboration and creating a communication continuum, as well as enhancing patient and physician education, goal setting and tracking outcomes ensure success for all stakeholders.”
According to the National Kidney Foundation, chronic kidney disease affects 26 million Americans, while millions more are at increased risk. It’s one of the many complications of hypertension, but it can also cause hypertension, and it often affects people with diabetes.
Diplomat said that in pilot studies, its CKD Navigator disease management program showed significant medication and medical cost savings while improving results among patients by incorporating medication therapy management, medication adherence tools and lifestyle management techniques.
“We have demonstrated the savings,” Diplomat VP clinical services Ron Alexander said in a statement. “Now, with the CareSource project, we plan to not only show good financial metrics, but also incorporate lifestyle information to gauge the program’s health effects.”